Solid Biosciences provided a corporate update highlighting its expanded clinical pipeline and 2025 objectives, focusing on genetic medicines for...

Silexion Therapeutics (NASDAQ: SLXN) announced promising preclinical results for SIL-204, its second-generation siRNA therapy targeting KRAS-mutated cancers. The data...

Radical Catheter Technologies, backed by NeuroTechnology Investors, received FDA 510(k) clearance for its 8F catheter, expanding its neurovascular product...

Brigham and Women’s Hospital has initiated enrollment for the Phase 3 REVEAL study of 124I-evuzamitide (AT-01), a diagnostic imaging...

The recent FDA workshop, “Building Quality into the Design and Conduct of Clinical Studies: Integrating Quality by Design (QbD)...

Glaukos Corporation announced positive clinical updates for its iDose® sustained-release drug delivery platform for glaucoma and ocular hypertension. The...

Omada Health’s analysis reveals that participants in their GLP-1 Enhanced Care Track maintained weight loss 16 weeks after discontinuing...

Umoja Biopharma, a clinical-stage company developing •in vivo• cell therapies, secured $100 million in Series C funding. The round...

Bayer AG announced progress in its pharmaceutical growth strategy at the 43rd J.P. Morgan Healthcare Conference, highlighting regulatory submissions...

Context Therapeutics has dosed the first patient in a Phase 1 clinical trial for CTIM-76, a T cell engager...